Novartis Acquires Mutant-Selective PI3Kα Inhibi...

By HEOR Staff Writer

March 23, 2026

Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Sy...
Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal...
Accelerating Patient Access: MHRA NICE Alignment Initiative
Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Di...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...